Apatinib induces apoptosis of breast cancer cells by redistribution of Fas into lipid rafts

doi:10.5246/jcps.2019.11.074

Abstract

Abstract:

Apatinib, an oral anti-angiogenic agent, has been shown to have anti-cancer effects for several cancer cell types. However, little is known about the direct anti-tumor activity of apatinib for breast cancer cells. Herein, the direct effect of apatinib on breast cancer cells and its mechanism of action were assessed. Cell viability was measured with a Cell Counting Kit-8. Cell apoptosis was assessed by flow cytometry. The expression of caspase-8 and the cleavage of poly ADP ribose polymerase were assessed by Western blotting analysis. Lipid rafts and Fas distribution were determined by immunofluorescence microscopy. Apatinib suppressed breast cancer cell proliferation in a dose-dependent manner. Furthermore, apatinib enhanced the aggregation of lipid rafts and the redistribution of Fas into lipid rafts. Pretreatment with methyl-β-cyclodextrin, a cholesterol-sequestering agent, significantlyreversed Fas redistribution and apatinib-induced apoptosis.In conclusion, these results demonstrated that apatinib induced apoptosis of breast cancer cells partially through recruitment of Fas into lipid rafts.

Key words: Apatinib, Breast cancer, Lipid rafts, Fas

CLC Number:

R969

Supporting:

Shunchao Yan, Xin Jiao, Na Li, Yangfan Du, Chengyao Jiang. Apatinib induces apoptosis of breast cancer cells by redistribution of Fas into lipid rafts[J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(11): 778-785.

References

[1] Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2017. CA Cancer J. Clin. 2017, 67, 7-30.

[2] Nagini, S. Breast cancer: current molecular therapeutic targets and new players. Anti Cancer Agents Med. Chem. 2017, 17, 152-163.

[3] Santos, R.; Ursu, O.; Gaulton, A.; Bento, A.P.; Donadi, R.S.; Bologa, C.G.; Karlsson, A.; Al-Lazikani, B.; Hersey, A.; Oprea, T.I.; Overington, J.P. A comprehensive map of molecular drug targets. Nat. Rev. Drug Discov. 2017, 16, 19-34.

[4] Paduch, R. The role of lymphangiogenesis and angiogenesis in tumor metastasis. Cell Oncol. 2016, 39, 397-410.

[5] Aalders, K.C.; Tryfonidis, K.; Senkus, E.; Cardoso, F. Anti-angiogenic treatment in breast cancer: Facts, successes, failures and future perspectives. Cancer Treat. Rev. 2017, 53, 98-110.

[6] Zhang, Y.; Han, C.; Li, J.; Zhang, L.; Wang, L.J.; Ye, S.S.; Hu, Y.; Bai, L. Efficacy and safety for Apatinib treatment in advanced gastric cancer: a real world study. Sci. Rep. 2017, 7, 13208.

[7] Janni, W.; Sarosiek, T.; Karaszewska, B.; Pikiel, J.; Staroslawska, E.; Potemski, P.; Salat, C.; Brain, E.; Caglevic, C.; Briggs, K.; Mahood, K.; DeSilvio, M.; Marini, L.; Papadimitriou, C. Final overall survival analysis of a phase II trial evaluating vinorelbine and lapatinib in women with ErbB2 overexpressing metastatic breast cancer. Breast. 2015, 24, 769-773.

[8] Liu, Z.; Chen, J.L.; Fang, Y.; Han, X.F.; Pan, H.M.; Han, W.D. The efficacy and safety of apatinib treatment for patients with unresectable or relapsed liver cancer: a retrospective study. J. Cancer. 2018, 9, 2773-2777.

[9] Scott, L.J. Apatinib: A review in advanced gastric cancer and other advanced cancers. Drugs. 2018, 78, 747-758.

[10] Hu, W.; Kavanagh, J.J. Anticancer therapy targeting the apoptotic pathway. Lancet Oncol. 2003, 4, 721-729.

[11] Nagata, S. Fas ligand-induced apoptosis. Annu. Rev. Genet. 1999, 33, 29-55.

[12] George, K.S.; Wu, S.Y. Lipid raft: A floating island of death or survival. Toxicol. Appl. Pharmacol. 2012, 259, 311-319.

[13] Mollinedo, F.; Gajate, C. Fas/CD95 death receptor and lipid rafts: new targets for apoptosis-directed cancer therapy. Drug Resist. Updat. 2006, 9, 51-73.

[14] Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394-424.

[15] Huang, L.H.; Wei, Y.Y.; Shen, S.P.; Shi, Q.W.; Bai, J.L.; Li, J.; Qin, S.K.; Yu, H.; Chen, F. Therapeutic effect of apatinib on overall survival is mediated by prolonged progression-free survival in advanced gastric cancer patients. Oncotarget. 2017, 8, 29346-29354.

[16] Li, J.; Qin, S.K.; Xu, J.M.; Guo, W.J.; Xiong, J.P.; Bai, Y.X.; Sun, G.P.; Yang, Y.; Wang, L.W.; Xu, N.; Cheng, Y.; Wang, Z.H.; Zheng, L.Z.; Tao, M.; Zhu, X.D.; Ji, D.M.; Liu, X.; Yu, H. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J. Clin. Oncol. 2013, 31, 3219-3225.

[17] Hu, X.C.; Zhang, J.; Xu, B.H.; Jiang, Z.F.; Ragaz, J.; Tong, Z.S.; Zhang, Q.Y.; Wang, X.J.; Feng, J.F.; Pang, D.M.; Fan, M.H.; Li, J.; Wang, B.Y.; Wang, Z.H.; Zhang, Q.L.; Sun, S.; Liao, C.M. Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer. Int. J. Cancer. 2014, 135, 1961-1969.

[18] Hu, X.C.; Cao, J.; Hu, W.W.; Wu, C.P.; Pan, Y.Y.; Cai, L.; Tong, Z.S.; Wang, S.S.; Li, J.; Wang, Z.H.; Wang, B.Y.; Chen, X.Y.; Yu, H. Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer. BMC Cancer. 2014, 14, 820.

[19] Gajate, C.; Gonzalez-Camacho, F.; Mollinedo, F. Lipid raft connection between extrinsic and intrinsic apoptotic pathways. Biochem. Biophys. Res. Commun. 2009, 380, 780-784.

[20] Gajate, C.; Mollinedo, F. Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood. 2007, 109, 711-719.

[21] Yan, S.C.; Qu, X.J.; Xu, L.; Che, X.F.; Ma, Y.J.; Zhang, L.Y.; Teng, Y.E.; Zou, H.W.; Liu, Y.P. Bufalin enhances TRAIL-induced apoptosis by redistributing death receptors in lipid rafts in breast cancer cells. Anticancer Drugs. 2014, 25, 683-689.

[22] Delmas, D.; Rébé, C.; Lacour, S.; Filomenko, R.; Athias, A.; Gambert, P.; Cherkaoui-Malki, M.; Jannin, B.; Dubrez-Daloz, L.; Latruffe, N.; Solary, E. Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells. J. Biol. Chem. 2003, 278, 41482-41490.